TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05356091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
Study: NCT05470296

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Move & Eat 2 Live
Description: American Indians suffer disproportionately from several chronic diseases that may be prevented with healthier modifiable factors. Nutrition, physical activity and a healthy weight are key factors that may prevent and reduce risk of disease incidence. The major goals of this project are to develop a culturally adapted intervention that addresses barriers and uses positive cultural values as guiding principles for behavior changes to enhance program retention and improve behaviors. This project will pilot a 12-week standard lifestyle intervention in American Indians.
Study: NCT05623020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
Study: NCT06340503

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Index Assessment (Control Arm)
Description: Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 6, 9 and 12 while on study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Surveys
Description: Various health surveys will be completed to assess participant health and physical activities.
Study: NCT05623020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Randomized
Study: NCT05416281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Vacuum
Description: Participants will be provided with a Roomba iRobot vacuum and will be asked to use the vacuum in their home for 8 weeks. Exposure to environmental exposures will be evaluated before and after the intervention using silicone wristbands.
Study: NCT05370248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal volume 6 ml/kg
Description: Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
Study: NCT06340503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Surveys
Description: Various health surveys will be completed to assess participant health and physical activities.
Study: NCT05370248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume 10 ml/kg
Description: Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
Study: NCT04896775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NiteCAPP CARES
Description: Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NiteCAPP SHARES
Description: Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
Study: NCT05163873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-peritoneal
Description: Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH
Study: NCT05314985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehab intervention
Description: Individual training program containing strengthening, sensori-motor, joint mobilisation and endurance exercises as well as educational inputs concerning perioperative procedure and instructions on e.g. how to walk with crutches.
Study: NCT06466317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Honey intake with walking exercise
Description: 20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines in addition to consuming natural honey (2ml/kg honey will be taken.. This dose will be divided into two halves, the first half will be taken at 7 am and the other half will be taken at 7 pm for 12 weeks)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise
Description: 20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines for 12 weeks)
Study: NCT06103955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Breathing Biofeedback system
Description: The biofeedback system provides information to the patient and physio about the muscle coordination of breathing.
Study: NCT05446870

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg by IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: According to local practice and at the choice of the investigator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avastin
Description: According to local practice and at the choice of the investigator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: 800 mg by IV infusion on Day 1 of each 21-day cycle
Study: NCT06382493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan-containing sequential H. pylori eradication therapy
Description: tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole-containing sequential H. pylori eradication therapy
Description: Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
Study: NCT05564598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV Cytotoxic T-Lymphocytes
Description: Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV Cytotoxic T-Lymphocytes
Description: Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-viral Therapy
Description: All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-viral Therapy
Description: All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-viral Therapy
Description: All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months
Study: NCT05446870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
Study: NCT05121675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroflow app: Mental health and wellbeing resources for adults
Description: The NeuroFlow app delivers resources on resilience training, mindfulness-based strategies and cognitive behavioral therapy to adults looking to support their mental health and wellbeing. The specific journey (i.e., content such as activities, videos, trackers, and journaling) is tailored to individuals based on depression and anxiety screeners administered upon signing up to the app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuroflow app: Mental health and wellbeing resources for adults
Description: The NeuroFlow app delivers resources on resilience training, mindfulness-based strategies and cognitive behavioral therapy to adults looking to support their mental health and wellbeing. The specific journey (i.e., content such as activities, videos, trackers, and journaling) is tailored to individuals based on depression and anxiety screeners administered upon signing up to the app.
Study: NCT04793464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotores de Salud
Description: The Promotores de Salud intervention is delivered by a paid Promotor(a) who is a trusted member of the community where the testing site is located. The intervention includes: (1) psychoeducation to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores are on-site at testing events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Services as usual, our control condition, includes strategies that are typically conducted by county and community-based organizations that serve under-represented groups to notify people of testing opportunities related to COVID-19. These include Facebook advertisements, email announcements, circulation to other community-based organizations and state agencies (e.g., Oregon Health Authority, county public health), and other flyer distribution means. This condition also includes a pamphlet about health behaviors and community resources handed out by testing facilitators at testing events.
Study: NCT05441358

Intervention type: PROCEDURE
Intervention: Open Heart Surgery
Description: Blood collection at 4 timepoints (prior to anesthesia induction, immediately post-protamine, 1-2 hours post protamine, and up to 48 hours post-surgical completion) to assess platelet function.
Study: NCT06058143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CLIF-LP
Description: CLIF-LP surgery method was applied

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLIF
Description: TLIF surgery method was applied
Study: NCT05353738

Intervention type: BIOLOGICAL
Intervention: Blood sample for research of anti-xoprs netralizing anti spike
Description: The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group).

Intervention type: BIOLOGICAL
Intervention: Blood sample for research of anti-xoprs netralizing anti spike
Description: The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group).

Intervention type: BIOLOGICAL
Intervention: Blood sample for research of anti-xoprs netralizing anti spike
Description: The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group).
Study: NCT04756089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic breast pump
Description: Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exogenous oxytocin intravenous infusion
Description: Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
Study: NCT05353738

Intervention type: OTHER
Intervention: Questionnaire
Description: Evaluation of vaccine efficacy in real life by filling out questionnaires
Study: NCT02899598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extra blood draw samples
Description: NEVER STARTED

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: extra amniotic fluid samples
Description: NEVER STARTED
Study: NCT05991050

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy-restricted diet
Description: Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy-restricted diet
Description: Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration
Description: For 8 weeks, WBV participants completed 3 supervised training sessions a week. The exercises were consisted of dynamic squats starting from upright position into the assigned degree of knee ﬂexion squats with 90° knee angle, semi-squats with 120° knee angle and heel elevation (calf-raise), each exercise was performed for 3 sets and each set consisted of 5 repetitions.
Study: NCT06498674

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Supplementary Pathological Examination
Description: For the same thyroid nodule, if there is discordance between the interpretations of AI-assisted ultrasound and traditional two-dimensional ultrasound, supplementary fine needle aspiration biopsy or intraoperative biopsy will be performed to clarify the nature of the nodule.

Intervention type: OTHER
Group type: OTHER
Intervention: No Need for Supplementary Pathological Examination
Description: For the same thyroid nodule, if there is discordance between the interpretations of AI-assisted ultrasound and traditional two-dimensional ultrasound, there is no need for supplementary fine needle aspiration biopsy or intraoperative biopsy.
Study: NCT06401772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intracranial Hypotension Targeted(IHT) Body Posture
Description: IHT therapy requires CSDH patients to raise their lower limbs 30° higher over the horizontal level of their head.For patients with unilateral CSDH, the head should be tilted towards the hematoma affected side and opposite side lying should be avoided as much as possible. For patients with bilateral CSDH, there is no need for the head lateralization.To avoid food reflux and aspiration pneumonia, IHT therapy was strictly prohibited within 2 hours after each meal
Study: NCT04125394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose
Description: Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
Study: NCT06094764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A
Description: The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group A will be fitted with a cooling and bio-harness. At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B
Description: The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group B will wear a bio-harness and no cooling vest.At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.